Using advanced HDX-MS and native MS techniques can improve the identification of potentially successful biologic drugs and de-risk CMC and clinical designs.
Jennifer S. Chadwick
Advertisement
Jennifer S. Chadwick, PhD, is director of biologic development at BioAnalytix.
Articles by Jennifer S. Chadwick
Advertisement
Latest Updated Articles
De-risking Biologics Development Through Advanced Mass Spectrometry ApproachesPublished: August 1st 2019 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
Industry Leaders Detail Transformational Strategies to Mainstream CAR-T Care
3
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
4
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
5
